Clinical Trial

Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding. This study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.
Trial Details
NCT Number NCT07746349
Lead Sponsor Sevil Cankaya
Conditions Uterine Fibroids (Leiomyoma), Uterine Myoma, Leiomyoma
Enrollment 80 participants
Start Date 2026-08-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05